dan-2163

Amisulpride (DAN 2163) (trade name Solian) is an antipsychotic drug sold by Sanofi-Aventis. It is not approved for use in the United States, but is approved for use in Europe and Australia for the treatment of psychoses and schizophrenia. Additionally, it is approved in Italy for the treatment of dysthymia (under the brand name Deniban). Amisulpride is a selective dopamine antagonist.

Aramisulpride (hydrochloride) is a 5-HT7 receptor antagonist with a Ki value of 22 nM. It also acts as a D2/D3 receptor antagonist, exhibiting a Ki value of 140 nM for D2 receptors and 13.9 nM for D3 receptors. This compound is utilized in the study of psychiatric disorders.

Amisulpride (Standard) is a reference standard for research and analysis in studies involving Amisulpride. Amisulpride (DAN 2163) (trade name Solian) is an antipsychotic drug sold by Sanofi-Aventis. It is not approved for use in the United States, but is approved for use in Europe and Australia for the treatment of psychoses and schizophrenia. Additionally, it is approved in Italy for the treatment of dysthymia (under the brand name Deniban). Amisulpride is a selective dopamine antagonist.